AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
ConditionColorectal Adenocarcinoma
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAkeso
About this trial
This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.
Eligibility criteria
Qualifiers
Signed informed consent.
Age ≥ 18 years and ≤ 75 years.
ECOG status of 0 or 1.
Estimated survival ≥ 3 months.
Disqualifiers
Previous (within 3 years) or concurrent other malignant tumors, excluding those that have been cured.
Participating in other interventional study within 4 weeks prior to the first study drug administration.
Palliative local treatment for non-target lesions within 2 weeks prior to the first administration; received non-specific immunomodulatory therapy within 2 weeks prior to the first administration.
Current presence of uncontrolled combined disease.
Trial design
Treatments tested in this trial
- AK112
- Oxaliplatin
- Irinotecan
- Leucovorin and 5-FU
- Bevacizumab
Treatment groups
560 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov